drugset / Trial / NCT03549260
Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Study to assess the LDL-C lowering efficacy of different doses of LIB003 administered every 4 weeks in subjects on stable statin and/or ezetimibe therapy
Timeline
- Start
- 2018-05-22
- Primary completion
- 2018-11-09
- Completion
- 2018-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | lerodalcibep | Protein / enzyme biologic | 150 mg | Subcutaneous |
| Subject | lerodalcibep | Protein / enzyme biologic | 300 mg | Subcutaneous |
| Subject | lerodalcibep | Protein / enzyme biologic | 350 mg | Subcutaneous |